Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.
Website: amicusrx.com


  • Good financial results growth rate 34.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (39.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.4% (LTM)
  • Share price is 153.4% higher than minimum and 1.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (183.5x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $4.8 mln (-0.140% of cap.)

Key Financials (Download financials)

Ticker: FOLD
Share price, USD:  (0.0%)14.29
year average price 8.74  


year start price 9.64 2025-02-13

min close price 5.64 2025-06-20

max close price 14.38 2026-01-14

current price 14.29 2026-02-13
Common stocks: 308 468 423

Dividend Yield:  0.0%
FCF Yield LTM: 0.4%
EV / LTM EBITDA: 183.5x
EV / EBITDA annualized: 31.9x
Last revenue growth (y/y):  +19.0%
Last growth of EBITDA (y/y):  +50.0%
Historical revenue growth:  +37.0%
Historical growth of EBITDA:  +41.9%
EV / Sales: 5.5x
Margin (EBITDA LTM / Revenue): 3.0%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 408
Net Debt ($m): 179
EV (Enterprise Value): 4 587
EBITDA LTM (млн $): 25
EV / LTM EBITDA: 183.5x
Price to Book: 19.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-23businesswire.com

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

2026-01-16zacks.com

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?

2025-12-16zacks.com

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?

2025-12-09zacks.com

The Best Cheap Stocks Under $10 to Buy in December and 2026

2025-12-04zacks.com

Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?

2025-11-10seekingalpha.com

Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-05zacks.com

Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues

2025-11-04zacks.com

Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates

2025-10-22seekingalpha.com

Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies

2025-09-09seekingalpha.com

Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-07-31 2024-11-06 2024-08-08 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-07
acceptedDate 2025-11-04 16:03:53 2025-07-31 16:02:39 2025-02-19 16:02:51 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21 2022-02-24 16:19:22 2021-03-01 16:21:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 169M 155M 528M 142M 127M 110M 399M 104M 95M 86M 329M 82M 306M 261M
costOfRevenue 21M 15M 53M 13M 13M 16M 37M 10M 9M 7M 39M 13M 34M 31M
grossProfit 148M 139M 475M 128M 113M 95M 362M 94M 85M 79M 291M 68M 271M 230M
grossProfitRatio 0.874 0.902 0.906 0.894 0.858 0.904 0.904 0.92 0.836
researchAndDevelopmentExpenses 23M 61M 109M 26M 25M 28M 152M 41M 35M 41M 277M 53M 272M 308M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 90M 85M 323M 75M 74M 88M 275M 66M 65M 74M 213M 47M 193M 156M
otherExpenses 0 4M 18M 0 -4M -5M 12M 4M -11M 1M 13M 1M 13M 12M
operatingExpenses 113M 149M 450M 101M 98M 116M 439M 106M 103M 117M 503M 102M 477M 477M
costAndExpenses 135M 164M 503M 120M 112M 132M 477M 116M 112M 124M 541M 115M 512M 508M
interestIncome 829 000 843 000 5M 1M 1M 2M 7M 1M 2M 2M 3M 563 000 509 000 3M
interestExpense 12M 12M 50M 13M 13M 12M 50M -13M 12M 12M 37M 10M 32M 22M
depreciationAndAmortization 2M 2M 9M 2M 2M 2M 8M 2M 2M -2M 5M 15M 6M 9M
ebitda 48M -6M 29M 22M 15M -20M -92M -29M -24M -40M -200M -18M -203M -243M
ebitdaratio 0.283 -0.037 0.153 0.135 -0.177 -0.282 -0.258 -0.462 -0.218
operatingIncome 34M -9M 25M 22M 15M -22M -77M -17M -19M -37M -212M -33M -206M -247M
operatingIncomeRatio 0.203 -0.061 0.153 0.118 -0.196 -0.164 -0.2 -0.433 -0.407
totalOtherIncomeExpensesNet 5000 -10M -54M -15M -15M -22M -73M -8M -12M -16M -30M 4M -35M -27M
incomeBeforeTax 34M -19M -29M 7M 108 000 -44M -150M -25M -41M -53M -242M -29M -242M -274M
incomeBeforeTaxRatio 0.203 -0.124 0.048 0.001 -0.395 -0.239 -0.429 -0.617 -0.358
incomeTaxExpense 17M 5M 27M 14M 16M 5M 1M 3M 3M -287 000 -5M 4M 9M 3M
netIncome 17M -24M -56M -7M -16M -48M -152M -22M -43M -53M -237M -33M -250M -277M
netIncomeRatio 0.102 -0.158 -0.048 -0.124 -0.439 -0.208 -0.457 -0.614 -0.407
eps 0.056 -0.08 -0.18 -0.022 -0.052 -0.16 -0.51 -0.073 -0.15 -0.18 -0.82 -0.12 -0.92 -1.07
epsdiluted 0.056 -0.08 -0.022 -0.052 -0.16 -0.073 -0.15 -0.18 -0.12
weightedAverageShsOut 308M 308M 304M 305M 304M 303M 295M 296M 293M 291M 289M 289M 271M 259M
weightedAverageShsOutDil 310M 308M 304M 305M 304M 303M 295M 296M 293M 291M 289M 289M 271M 259M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-28 2023-03-01 2022-02-24 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -44M -43M -34M -32M -19M
ebit 21M -100M -205M -209M -252M
nonOperatingIncomeExcludingInterest 4M 23M -7M 3M 5M
netIncomeFromContinuingOperations -56M -152M -237M -250M -277M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -56M -152M -237M -250M -277M
epsDiluted -0.18 -0.51 -0.82 -0.92 -1.07

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-07-31 2024-11-06 2024-08-08 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-07
acceptedDate 2025-11-04 16:03:53 2025-07-31 16:02:39 2025-02-19 16:02:51 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21 2022-02-24 16:19:22 2021-03-01 16:21:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 191M 159M 214M 234M 209M 210M 247M 263M 211M 161M 149M 278M 245M 163M
shortTermInvestments 73M 72M 36M 16M 51M 30M 39M 17M 54M 107M 145M 77M 237M 320M
cashAndShortTermInvestments 264M 231M 250M 250M 260M 240M 286M 280M 266M 267M 294M 355M 482M 483M
netReceivables 114M 106M 101M 98M 85M 76M 88M 73M 64M 68M 66M 52M 53M 47M
inventory 178M 155M 119M 115M 81M 61M 60M 57M 51M 27M 24M 13M 27M 20M
otherCurrentAssets 38M 46M 35M 35M 35M 54M 50M 53M 52M 37M 40M 38M 0 0
totalCurrentAssets 594M 538M 505M 498M 462M 431M 483M 463M 433M 400M 424M 459M 597M 579M
propertyPlantEquipmentNet 49M 51M 52M 54M 54M 55M 58M 61M 58M 60M 60M 62M 63M 67M
goodwill 198M 198M 198M 198M 198M 198M 198M 198M 198M 198M 198M 198M 198M 198M
intangibleAssets 15M 16M 17M 18M 19M 20M 20M 21M 22M 23M 23M 23M 23M 23M
goodwillAndIntangibleAssets 213M 213M 215M 216M 217M 217M 218M 219M 220M 221M 221M 221M 221M 221M
longTermInvestments 0 3M 0 0 3M 3M 0 3M 3M 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 -3M -3M 0 0 0 0 0
otherNonCurrentAssets 13M 10M 14M 19M 14M 15M 19M 21M 19M 20M 19M 18M 24M 19M
totalNonCurrentAssets 275M 277M 280M 288M 288M 291M 295M 301M 297M 301M 300M 301M 308M 307M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 869M 815M 785M 787M 749M 722M 778M 764M 730M 701M 724M 760M 905M 887M
accountPayables 19M 14M 13M 13M 32M 9M 15M 23M 14M 25M 15M 12M 22M 17M
shortTermDebt 9M 9M 0 17M 16M 8M 0 8M 8M 8M 0 8M 0 0
taxPayables 0 0 18M 0 0 0 12M 0 0 0 6M 0 6M 11M
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 5M 0 0
otherCurrentLiabilities 171M 145M 41M 128M 120M 125M 49M 139M 138M 105M 33M 140M 28M 27M
totalCurrentLiabilities 199M 168M 149M 158M 168M 142M 168M 169M 159M 138M 139M 165M 146M 130M
longTermDebt 434M 435M 390M 436M 436M 388M 388M 447M 444M 444M 392M 443M 389M 389M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 6M 6M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 -6M -6M 0 5M 5M 5M 5M
otherNonCurrentLiabilities 5M 9M 7M 13M 13M 61M 13M 15M 15M 16M 14M 438M 14M 31M
totalNonCurrentLiabilities 439M 443M 442M 450M 449M 449M 450M 461M 459M 460M 462M 462M 452M 470M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 51M 52M 54M 55M 55M 48M 57M 60M 59M 59M 60M 60M 51M 52M
totalLiabilities 638M 611M 591M 608M 617M 591M 618M 631M 619M 598M 601M 627M 598M 600M
preferredStock 0 0 0 0 0 0 0 7M 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M
retainedEarnings -2 769M -2 786M -2 740M -2 755M -2 748M -2 732M -2 684M -2 650M -2 629M -2 585M -2 532M -2 477M -2 296M -2 045M
accumulatedOtherComprehensiveIncomeLoss 23M 31M 5M 25M 9M 7M 5M -7M 4M -7M -12M -39M 5M 8M
othertotalStockholdersEquity 2 974M 2 957M 2 906M 2 869M 2 854M 2 781M 2 733M 2 692M 2 645M
totalStockholdersEquity 230M 204M 194M 179M 133M 131M 160M 133M 112M 103M 123M 133M 307M 286M
totalEquity 230M 204M 194M 179M 133M 131M 160M 133M 112M 103M 123M 133M 307M 286M
totalLiabilitiesAndStockholdersEquity 869M 815M 787M 749M 722M 764M 730M 701M 760M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 869M 815M 785M 787M 749M 722M 778M 764M 730M 701M 724M 760M 905M 887M
totalInvestments 73M 76M 36M 16M 54M 33M 39M 17M 54M 107M 145M 77M 237M 320M
totalDebt 443M 443M 444M 445M 444M 444M 445M 454M 452M 452M 452M 451M 440M 442M
netDebt 252M 285M 230M 211M 235M 235M 198M 191M 241M 291M 303M 173M 195M 278M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-28 2023-03-01 2022-02-24 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 101M 88M 66M 53M 47M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 35M 30M
totalPayables 31M 28M 43M 51M 44M
otherPayables 18M 12M 27M 30M 27M
accruedExpenses 68M 83M 55M 59M 52M
capitalLeaseObligationsCurrent 8M 8M 9M 7M 7M
capitalLeaseObligationsNonCurrent 45M 49M 52M 43M 46M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 926M 2 836M 2 665M 2 595M 2 309M
otherTotalStockholdersEquity 71 000 71 000 83 000 83 000 12M

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-07-31 2024-11-06 2024-08-08 2024-05-09 2023-11-08 2023-08-08 2023-05-10 2022-11-07
acceptedDate 2025-11-04 16:03:53 2025-07-31 16:02:39 2025-02-19 16:02:51 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21 2022-02-24 16:19:22 2021-03-01 16:21:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 17M -24M -56M -7M -16M -48M -152M -22M -43M -53M -237M -33M -250M -277M
depreciationAndAmortization 2M 2M 9M 2M 2M 2M 8M 2M 2M 1M 5M 1M 6M 9M
deferredIncomeTax 0 0 0 0 0 5M -5M 3M 20M -5M 9000 0 34 000 -155 000
stockBasedCompensation 18M 18M 85M 19M 16M 31M 86M 17M 17M 35M 77M 15M 58M 49M
changeInWorkingCapital -10M -29M -99M 11M 11M -22M -48M -33M -5M -3M -40M -3M -19M -32M
accountsReceivables -8M -12M -19M 0 -10M 10M -20M -11M 4M -1M -17M -3M -8M -11M
inventory -36M -23M -74M 0 -25M -2M -45M -15M -24M -3M -5M 1M -8M -5M
accountsPayables 31M 10M -17M -3M 27M -24M 49M 9M 32M -72 000 -6M 3M 7M -11M
otherWorkingCapital 4M -4M 11M 14M 19M -6M -32M -16M -16M 1M -11M -4M -10M -6M
otherNonCashItems 8M 8M 28M -48M 38M 60M 41M -6M -7M 7M 28M 9M 2M 18M
netCashProvidedByOperatingActivities 36M -27M -34M -23M 23M -30M -69M -38M -16M -18M -167M -12M -202M -233M
investmentsInPropertyPlantAndEquipment -382 000 -2M -4M 3M -1M -2M -7M -2M -2M -2M -4M 0 -4M -3M
acquisitionsNet 0 0 0 0 0 0 0 2M 2M 0 3M 0 0 0
purchasesOfInvestments -18M -14M -115M -5M -44M -30M -92M -17M -20M -17M -243M -1M -341M -365M
salesMaturitiesOfInvestments 17M 11M 118M 40M 23M 39M 197M 54M 72M 55M 336M 76M 424M 355M
otherInvestingActivites 0 0 -3M -1M 9M -2M -2M 0 137 000
netCashUsedForInvestingActivites -1M -6M 34M -22M 8M 36M 50M 36M 75M
debtRepayment -17 000 -8000 24 000 -36 000 -42 000 -31 000 -23 000 -28 000 -51 000
commonStockIssued 339 000 40 000 19M 863 000 3M 37M 24M 2M 0
commonStockRepurchased 0 0 0 0 0 -17M 0 -2M -1M -13M -11M 0 0 0
dividendsPaid 0 0 0 0 0 0 -1M 0 0
otherFinancingActivites -2M -432 000 -987 000 -821 000 -17M 6M 2M 3M -508 000
netCashUsedProvidedByFinancingActivities -1M -400 000 18M -857 000 -13M 38M 24M -8M -559 000
effectOfForexChangesOnCash -1M 10M -4M -5M -294 000 -2M 6M 17M -8M 2M -15M -21M -5M 4M
netChangeInCash 32M -23M -33M 24M -426 000 -37M 97M 52M 49M 12M -96M 42M 83M 20M
cashAtEndOfPeriod 191M 162M 217M 237M 209M 210M 250M 266M 214M 165M 153M 282M 249M 166M
cashAtBeginningOfPeriod 159M 185M 250M 212M 210M 247M 153M 214M 165M 153M 249M 240M 166M 146M
operatingCashFlow 36M -27M -34M -23M 23M -30M -69M -38M -16M -18M -167M -12M -202M -233M
capitalExpenditure -382 000 -2M -4M -356 000 -1M -2M -7M -2M -2M -2M -4M 0 -4M -3M
freeCashFlow 35M -29M -37M -23M 22M -32M -77M -40M -18M -20M -170M -12M -206M -237M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-28 2023-03-01 2022-02-24 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -560 000 98M 92M 79M -14M
netDebtIssuance -97 000 -21M -283 000 -479 000 231M
longTermNetDebtIssuance -97 000 -21M -283 000 -479 000 231M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 27M 103M -7M 200M 0
netCommonStockIssuance 27M 93M -7M 200M 0
commonStockIssuance 27M 93M 4M 200M 0
netPreferredStockIssuance 0 10M 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -22M -21M 0 13M 32M
netCashProvidedByFinancingActivities 5M 62M -7M 212M 263M
incomeTaxesPaid 8M 9M 1M 20M 10M
interestPaid 59M 36M 34M 30M 25M

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-05 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-04 16:03 ET
Amicus Therapeutics reported for 2025 q3
SEC form 8
2025-11-04 07:39 ET
Amicus Therapeutics published news for 2025 q3
SEC form 8
2025-11-04 07:39 ET
Amicus Therapeutics reported for 2025 q3
SEC form 8
2025-11-04 07:39 ET
Amicus Therapeutics published news for 2025 q3
SEC form 10
2025-07-31 20:02 ET
Amicus Therapeutics reported for 2025 q2
SEC form 8
2025-07-31 11:01 ET
Amicus Therapeutics published news for 2025 q2
SEC form 8
2025-07-31 11:01 ET
Amicus Therapeutics reported for 2025 q2
SEC form 8
2025-07-31 11:01 ET
Amicus Therapeutics published news for 2025 q2
SEC form 8
2025-06-05 20:01 ET
Amicus Therapeutics published news for 2025 q1
SEC form 10
2025-05-01 20:02 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics reported for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 10
2024-11-06 16:02 ET
Amicus Therapeutics reported for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics published news for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics reported for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics published news for 2024 q3
SEC form 10
2024-08-08 16:02 ET
Amicus Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Amicus Therapeutics published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 10
2024-02-28 16:08 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics reported for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 10
2023-11-08 16:02 ET
Amicus Therapeutics published news for 2023 q3
SEC form 8
2023-11-08 07:00 ET
Amicus Therapeutics reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Amicus Therapeutics published news for 2023 q3
SEC form 10
2023-08-08 16:02 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-08-08 07:00 ET
Amicus Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-07-13 17:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-06-27 07:01 ET
Amicus Therapeutics published news for 2023 q1
SEC form 6
2023-06-13 16:30 ET
Amicus Therapeutics published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Amicus Therapeutics published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Amicus Therapeutics reported for 2023 q1
SEC form 6
2023-03-27 07:00 ET
Amicus Therapeutics published news for 2022 q4
SEC form 10
2023-03-01 16:07 ET
Amicus Therapeutics reported for 2022 q4
SEC form 6
2023-03-01 07:01 ET
Amicus Therapeutics published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Amicus Therapeutics reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Amicus Therapeutics reported for 2022 q4
SEC form 6
2023-02-22 17:27 ET
Amicus Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 07:01 ET
Amicus Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Amicus Therapeutics published news for 2022 q4
SEC form 6
2022-12-28 17:00 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-12-16 08:17 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-16 07:01 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 14:31 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 07:22 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 07:01 ET
Amicus Therapeutics published news for 2022 q3
SEC form 10
2022-11-07 06:04 ET
Amicus Therapeutics reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Amicus Therapeutics reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Amicus Therapeutics reported for 2022 q3
SEC form 6
2022-10-28 17:18 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-09-14 07:00 ET
Amicus Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 16:08 ET
Amicus Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 07:01 ET
Amicus Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Amicus Therapeutics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Amicus Therapeutics reported for 2022 q2
SEC form 6
2022-08-01 17:10 ET
Amicus Therapeutics published news for 2022 q2
SEC form 6
2022-06-10 16:05 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 16:05 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-05-10 16:01 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-05-09 12:54 ET
Amicus Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 07:00 ET
Amicus Therapeutics published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-04-26 16:38 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 16:19 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 07:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 07:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2021-12-03 07:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-11-18 07:01 ET
Amicus Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 16:10 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 07:07 ET
Amicus Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-09-29 09:28 ET
Amicus Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:10 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 07:02 ET
Amicus Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-08-02 07:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-06-14 07:27 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-06-08 07:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 16:06 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-05-10 07:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-05-03 07:01 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 16:17 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-03-01 16:21 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-03-01 07:00 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-02-11 16:01 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-02-08 14:30 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 07:00 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2020-12-02 07:00 ET
Amicus Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:05 ET
Amicus Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 07:00 ET
Amicus Therapeutics published news for 2020 q3